LONDON – New data from a randomized community study involving more than half a million people has shown that of 92,116 who had symptomatic COVID-19, 38% were still reporting symptoms 12 weeks later.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: BD, Cardiofocus, Flo Health, Hologic, Innova, Integrity Implants, New View Surgical, Penumbra.
Although the U.S. CDC considers myocarditis to be a rare event linked to mRNA COVID-19 vaccines, the FDA is adding a warning about the adverse event to its doctor and patient fact sheets for the vaccines.
It has been a bumpy rollercoaster ride for many biopharma companies throughout the pandemic, but overall, the 17 firms that make up BioWorld’s Infectious Disease Index are coming out ahead this year with stocks up by 44.8%.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aarkus, Aleta, Alzheon, Celsion, Cerecor, Chemomab, Cocrystal, Dermtech, Etherna, Kedrion, Liminal, Mercaptor, Microbiotica, Mynd, Public Health Vaccines, Qu, Recursion, Scancell, Sorrento, SQZ, Tessa, Titan, Tiziana, Xenter.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Corelink, Fist Assist Devices, Onkos Surgical, Phase Scientific.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aidoc, Aptar, Avania, Garwood, Icometrix, Imarc, Integrum, Mirador, Prognos, Sorrento Therapeutics, Thermo Fisher Scientific, Voluntis.